S&P 500   3,329.64 (+0.00%)
DOW   29,335.00 (-0.04%)
QQQ   223.70 (+0.14%)
FB   221.46 (-0.31%)
MSFT   167.75 (+0.39%)
GOOGL   1,483.25 (+0.25%)
AMZN   1,870.54 (+0.31%)
CGC   24.52 (-1.49%)
NVDA   248.94 (-0.14%)
BABA   221.92 (-2.42%)
MU   58.64 (+1.70%)
GE   11.73 (-0.76%)
TSLA   542.98 (+6.36%)
AMD   51.20 (+0.53%)
T   38.53 (+0.39%)
ACB   2.04 (-4.23%)
F   9.18 (+0.22%)
NFLX   336.41 (-0.96%)
BAC   34.52 (-0.58%)
GILD   62.78 (-0.32%)
DIS   143.83 (-0.35%)
S&P 500   3,329.64 (+0.00%)
DOW   29,335.00 (-0.04%)
QQQ   223.70 (+0.14%)
FB   221.46 (-0.31%)
MSFT   167.75 (+0.39%)
GOOGL   1,483.25 (+0.25%)
AMZN   1,870.54 (+0.31%)
CGC   24.52 (-1.49%)
NVDA   248.94 (-0.14%)
BABA   221.92 (-2.42%)
MU   58.64 (+1.70%)
GE   11.73 (-0.76%)
TSLA   542.98 (+6.36%)
AMD   51.20 (+0.53%)
T   38.53 (+0.39%)
ACB   2.04 (-4.23%)
F   9.18 (+0.22%)
NFLX   336.41 (-0.96%)
BAC   34.52 (-0.58%)
GILD   62.78 (-0.32%)
DIS   143.83 (-0.35%)
S&P 500   3,329.64 (+0.00%)
DOW   29,335.00 (-0.04%)
QQQ   223.70 (+0.14%)
FB   221.46 (-0.31%)
MSFT   167.75 (+0.39%)
GOOGL   1,483.25 (+0.25%)
AMZN   1,870.54 (+0.31%)
CGC   24.52 (-1.49%)
NVDA   248.94 (-0.14%)
BABA   221.92 (-2.42%)
MU   58.64 (+1.70%)
GE   11.73 (-0.76%)
TSLA   542.98 (+6.36%)
AMD   51.20 (+0.53%)
T   38.53 (+0.39%)
ACB   2.04 (-4.23%)
F   9.18 (+0.22%)
NFLX   336.41 (-0.96%)
BAC   34.52 (-0.58%)
GILD   62.78 (-0.32%)
DIS   143.83 (-0.35%)
S&P 500   3,329.64 (+0.00%)
DOW   29,335.00 (-0.04%)
QQQ   223.70 (+0.14%)
FB   221.46 (-0.31%)
MSFT   167.75 (+0.39%)
GOOGL   1,483.25 (+0.25%)
AMZN   1,870.54 (+0.31%)
CGC   24.52 (-1.49%)
NVDA   248.94 (-0.14%)
BABA   221.92 (-2.42%)
MU   58.64 (+1.70%)
GE   11.73 (-0.76%)
TSLA   542.98 (+6.36%)
AMD   51.20 (+0.53%)
T   38.53 (+0.39%)
ACB   2.04 (-4.23%)
F   9.18 (+0.22%)
NFLX   336.41 (-0.96%)
BAC   34.52 (-0.58%)
GILD   62.78 (-0.32%)
DIS   143.83 (-0.35%)
Log in
(Ad)
A brand-new technology - code named "Halo-Fi" - could kill off your overpriced cable company for good... beaming lightning-fast internet to your home for an estimated $7 a month.

This is undoubtedly the beginning of the end for "Big 3" internet providers.

Forward-thinking investors in Halo-Fi are lining up to get rich before January 30th.

NASDAQ:CTXR - Citius Pharmaceuticals Stock Price, Forecast & News

$1.17
+0.03 (+2.63 %)
(As of 01/21/2020 12:46 PM ET)
Today's Range
$1.10
Now: $1.17
$1.24
50-Day Range
$0.42
MA: $0.79
$1.14
52-Week Range
$0.40
Now: $1.17
$1.59
Volume407,079 shs
Average Volume867,535 shs
Market Capitalization$33.85 million
P/E RatioN/A
Dividend YieldN/A
Beta1.05
Citius Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CTXR
CUSIPN/A
Phone908-967-6677

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.84 per share

Profitability

Net Income$-15,560,000.00

Miscellaneous

Employees7
Market Cap$33.85 million
Next Earnings Date2/13/2020 (Estimated)
OptionableNot Optionable

Receive CTXR News and Ratings via Email

Sign-up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter.


(Ad)


Join a small community of investors looking for the next big winner. Every Sunday reveals 3 compelling stocks that should be on your radar for the week ahead. Sign up here to see what stocks have made it to our watchlist this week.

Citius Pharmaceuticals (NASDAQ:CTXR) Frequently Asked Questions

What is Citius Pharmaceuticals' stock symbol?

Citius Pharmaceuticals trades on the NASDAQ under the ticker symbol "CTXR."

When did Citius Pharmaceuticals' stock split? How did Citius Pharmaceuticals' stock split work?

Shares of Citius Pharmaceuticals reverse split before market open on Friday, June 9th 2017. The 1-15 reverse split was announced on Thursday, June 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 8th 2017. An investor that had 100 shares of Citius Pharmaceuticals stock prior to the reverse split would have 7 shares after the split.

When is Citius Pharmaceuticals' next earnings date?

Citius Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Citius Pharmaceuticals.

What price target have analysts set for CTXR?

2 brokers have issued 1 year price targets for Citius Pharmaceuticals' shares. Their forecasts range from $3.00 to $7.00. On average, they expect Citius Pharmaceuticals' share price to reach $5.00 in the next twelve months. This suggests a possible upside of 327.4% from the stock's current price. View Analyst Price Targets for Citius Pharmaceuticals.

What is the consensus analysts' recommendation for Citius Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Citius Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Citius Pharmaceuticals.

Has Citius Pharmaceuticals been receiving favorable news coverage?

Media headlines about CTXR stock have trended neutral recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Citius Pharmaceuticals earned a news impact score of 0.5 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Citius Pharmaceuticals.

Are investors shorting Citius Pharmaceuticals?

Citius Pharmaceuticals saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,250,000 shares, an increase of 303.5% from the December 15th total of 309,800 shares. Based on an average daily volume of 360,700 shares, the days-to-cover ratio is currently 3.5 days. Approximately 8.1% of the shares of the stock are short sold. View Citius Pharmaceuticals' Current Options Chain.

Who are some of Citius Pharmaceuticals' key competitors?

What other stocks do shareholders of Citius Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Citius Pharmaceuticals investors own include Progenics Pharmaceuticals (PGNX), Real Goods Solar (RGSE), SCYNEXIS (SCYX), Opko Health (OPK), Zynerba Pharmaceuticals (ZYNE), Canopy Growth (CGC), Cronos Group (CRON), Melinta Therapeutics (MLNT), Strongbridge Biopharma (SBBP) and SenesTech (SNES).

Who are Citius Pharmaceuticals' key executives?

Citius Pharmaceuticals' management team includes the folowing people:
  • Mr. Leonard L. Mazur, Exec. Chairman & Sec. (Age 74)
  • Mr. Myron Z. Holubiak, Pres, CEO & Director (Age 72)
  • Mr. Jaime Bartushak, CFO, Chief Accounting Officer & Principal Financial Officer (Age 51)
  • Mr. Gary F. Talarico, Exec. VP of Operations (Age 64)
  • Mr. Andrew Scott, VP of Corp. Devel.

How do I buy shares of Citius Pharmaceuticals?

Shares of CTXR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Citius Pharmaceuticals' stock price today?

One share of CTXR stock can currently be purchased for approximately $1.17.

How big of a company is Citius Pharmaceuticals?

Citius Pharmaceuticals has a market capitalization of $33.85 million. The company earns $-15,560,000.00 in net income (profit) each year or ($1.17) on an earnings per share basis. Citius Pharmaceuticals employs 7 workers across the globe.View Additional Information About Citius Pharmaceuticals.

What is Citius Pharmaceuticals' official website?

The official website for Citius Pharmaceuticals is http://www.citiuspharma.com/.

How can I contact Citius Pharmaceuticals?

Citius Pharmaceuticals' mailing address is 11 Commerce Drive First Floor, Cranford NJ, 07016. The company can be reached via phone at 908-967-6677.


MarketBeat Community Rating for Citius Pharmaceuticals (NASDAQ CTXR)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  152 (Vote Outperform)
Underperform Votes:  185 (Vote Underperform)
Total Votes:  337
MarketBeat's community ratings are surveys of what our community members think about Citius Pharmaceuticals and other stocks. Vote "Outperform" if you believe CTXR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTXR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel